SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete (Q36945310)
Jump to navigation
Jump to search
scientific article published on 04 August 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete |
scientific article published on 04 August 2008 |
Statements
1 reference
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete (English)
1 reference
Julio Rosenstock
1 reference
Priscilla Hollander
1 reference
Soazig Chevalier
1 reference
Ali Iranmanesh
1 reference
SERENADE Study Group
1 reference
1 reference
Identifiers
1 reference